The identification of Omicron is a testament to the importance of broad genomic surveillance. Without the efforts of the South African scientists who identified and reported it, nations would not have been able to prepare for Omicron’s potential impact—and start looking for it themselves. Its detection is a clear sign that genomic surveillance is working and that we must keep supporting it as the pandemic wears on.

This isn’t the last time a new coronavirus variant will emerge—as long as people around the world remain unvaccinated, people will continue to get infected, which will give rise to new variants. As Omicron is illustrating now, no matter where variants are first identified, they can spread across the globe quickly. That’s why it’s essential that all countries do their part in sequencing samples and sharing data.

The U.S. has come a long way in terms of improving its genomic surveillance of the virus, which was widely criticized throughout the pandemic for being too slow and patchy, especially for a country with so many infections and unvaccinated people. In December 2020, the U.S. ranked 43^rd among countries sequencing and sharing COVID samples. By April 2021, it had inched up to 33^rd. Given the country’s leadership in the Human Genome Project, wrote Case Western Reserve University scientists Dana C. Crawford and Scott Williams in PLOS Genetics this past July, the dearth of U.S. sequencing data during the COVID pandemic is “unbelievable and problematic.”

Crawford, a professor at Case Western’s medical school, told me in an email that when they wrote the article, the U.S. was sequencing fewer samples compared to other countries, its sequencing efforts varied dramatically across states, and there was no national coordinated sequencing pipeline. This “meant that the virus could mutate into a more dangerous form undetected, making it very difficult for public health officials to respond to the new strain before it overwhelms local hospitals,” she says.

But now, says Crawford, the U.S. “is no longer behind other countries in genomic surveillance for SARS-CoV-2.” One reason is that the CDC is now coordinating a genomic surveillance effort that involves samples from all states and territories. At a briefing on Tuesday, CDC director Rochelle Walensky said that 80,000 samples are being sequenced each week—about one in every seven positive samples. The U.S. currently ranks 21^st among nations sequencing COVID samples (Iceland, Denmark, and New Zealand are leading the way). Walensky also said at the briefing that the CDC would expand virus surveillance at four of the nation’s busiest international airports: JFK, San Francisco, Newark, and Atlanta. These efforts are supported by $1.7 billion in funding that the Biden administration pledged in April.

There’s still plenty of room for improvement. Crawford points out that the coronavirus sequences from U.S. samples aren’t attached to any clinical data, like information on disease severity and vaccine effectiveness. As a result, the sequences can only tell us about the presence of new strains and changes in their frequency over time, but not the real-world impact of a particular variant. “Knowing the viral sequence is good,” she says, “but without linked clinical data, it is not useful for understanding the likelihood of changing the course of the pandemic.”

Other experts have argued that funding isn’t being used and distributed quickly enough and that sequencing centers need to coordinate more closely. Some have pointed out that sequencing ability is uneven across states, meaning that variants that crop up in low-surveillance areas may be missed. Importantly, sequencing isn’t possible without widespread, fast, and affordable testing, which is still out of reach for many Americans.

Nevertheless, the detection of Omicron in California on Wednesday is proof that the CDC’s surveillance system is working. “The US is now in a position to quickly identify potentially new dangerous strains that may arise in this country, giving us the opportunity to warn other countries about its existence much like South Africa has done with Omicron,” says Crawford. Even after the pandemic, she adds, the U.S. pipeline can “serve as a blueprint for genomic surveillance of other emerging infectious diseases”—so long as there’s continued support for the technology and expertise.

Thanks for reading, and please reach out if you have any questions or comments—I’d love to hear from you.

Stay safe out there,

Yasmin

@yeahyeahyasmin

DIGITAL HEALTH

Owlet pulls smart baby socks from the market after FDA warning. The baby-monitoring company Owlet has pulled its smart socks from the market, following a warning letter from the FDA and a subsequent plunge in stock price. Sent in October, the warning letter stated that Owlet didn’t have regulatory clearance to sell its smart socks, which are subject to the FDA’s approval because they’re considered “devices”—products intended to diagnose and address disease. The socks were meant to measure the baby’s heart rate, skin temperature, blood oxygenation, and sleep data. (Mobi Health News)

INDICATIONS

Top vaccine makers announce plans for Omicron vaccine. In response to Omicron, the world’s leading vaccine makers shared predictions and plans for the future of their coronavirus vaccines. On November 26, Moderna released a three-pronged plan to address Omicron that includes testing higher doses, developing multivalent vaccines, and making an Omicron-specific vaccine. In an interview with FT, Moderna CEO Stéphane Bancel said he thinks there “is going to be a material drop” in vaccine effectiveness. Pfizer said it can be ready to adapt a vaccine to Omicron within six weeks, and both AstraZeneca and Johnson & Johnson are testing their vaccines against Omicron and starting development on a new vaccine against the variant. Pfizer and Moderna announced similar plans to test Delta-specific vaccines when the variant emerged earlier this year, though some scientists were skeptical about whether they were needed. (Fierce Pharma)

GlaxoSmithKline poaches Pfizer’s vaccine lead to boost mRNA vaccine research. On Tuesday, British drug giant GSK announced its newest global head of vaccines R&D: Philip Dormitzer, former chief scientific officer of Pfizer’s viral vaccines unit. Poaching Dormitzer is seen as an investment in the future of GSK’s mRNA-based vaccines, which the company has previously touted as one of its key research areas. At Pfizer, Dormitzer helped lead the development of the mRNA-based coronavirus vaccine; he was also involved in making vaccines against respiratory syncytial virus (RSV), which GSK is also pursuing. (Endpoints News)

THE BIG PICTURE

Antiviral pills for COVID are a bigger deal than most think. Compared to the exuberant reception the COVID vaccines received around the globe, the reaction to new antivirals like Merck’s molnupiravir and Pfizer’s Paxlovid has been rather dull. But they warrant much more excitement, argues physician Monica Gandhi in The Atlantic: For starters, they can help prevent severe disease in people who are unvaccinated—which includes millions around the world who haven’t had the chance to get vaccinated. Unlike the vaccines, their effectiveness doesn’t change when the virus mutates. And, in people with breakthrough infections, they could help shorten symptoms as well as quickly bring down viral load, reducing the chances of transmission. This week, an advisory panel recommended that the FDA authorize molnupiravir, and Paxlovid is in review. One limitation worth noting, as the New York Times pointed out, is that these drugs are meant to be administered early on in an infection, so access to quick and accurate COVID testing will be essential for them to be effective.

REQUIRED READING

Singapore doctor: Omicron will likely ‘dominate and overwhelm’ the world by spring, by Chris Morris

New Omicron travel restrictions are threatening the tourism industry, by David Koenig, Yuri Kageyama, and the Associated Press

With federal COVID sick leave gone, ill workers feel pressure to go to work, by Rae Ellen Bichell and Kaiser Health News